Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Scheele

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Vaccines|February 26, 2022
What Drives the Value of a <i>Shigella</i> Vaccine?William P Hausdorff, Suzanne Scheele, Birgitte K Giersing
Plos Neglected Tropical Diseases|September 12, 2023
Shigella and childhood stunting: Evidence, gaps, and future research directionsKaroun H Bagamian, John D Anderson Iv, Gabriela Blohm, et al.
Bulletin of the World Health Organization|April 21, 2009
New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of KenyaJohn Mansoer, Suzanne Scheele, Katherine Floyd, et al.
Vaccine|October 16, 2024
MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settingsLauren M K Mason, Estefania Betancur, Margarita Riera-Montes, et al.
The Lancet. Global Health|May 18, 2023
Projecting the long-term economic benefits of reducing Shigella-attributable linear growth faltering with a potential vaccine: a modelling studyChloe Puett, John D Anderson, Karoun H Bagamian, et al.
The Lancet. Global Health|May 18, 2023
Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling studyJohn D Anderson, Karoun H Bagamian, Clint J Pecenka, et al.
Vaccine|October 12, 2023
Vaccine value profile for ShigellaWilliam P Hausdorff, John D Anderson, Karoun H Bagamian, et al.
Bulletin of the World Health Organization|January 2, 2024
Reassessing potential economic value and health impact of effective <i>Shigella</i> vaccinesWilliam P Hausdorff, John D Anderson, A Louis Bourgeois, et al.
Vaccine|July 13, 2024
Vaccine value profile for herpes simplex virusChristine Johnston, Suzanne Scheele, Laura Bachmann, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift AssaysSuzanne Scheele, Jennifer A Geiger, Amy E DeRocher, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Vaccines|February 26, 2022
What Drives the Value of a <i>Shigella</i> Vaccine?William P Hausdorff, Suzanne Scheele, Birgitte K Giersing
Plos Neglected Tropical Diseases|September 12, 2023
Shigella and childhood stunting: Evidence, gaps, and future research directionsKaroun H Bagamian, John D Anderson Iv, Gabriela Blohm, et al.
Bulletin of the World Health Organization|April 21, 2009
New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of KenyaJohn Mansoer, Suzanne Scheele, Katherine Floyd, et al.
Vaccine|October 16, 2024
MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settingsLauren M K Mason, Estefania Betancur, Margarita Riera-Montes, et al.
The Lancet. Global Health|May 18, 2023
Projecting the long-term economic benefits of reducing Shigella-attributable linear growth faltering with a potential vaccine: a modelling studyChloe Puett, John D Anderson, Karoun H Bagamian, et al.
The Lancet. Global Health|May 18, 2023
Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling studyJohn D Anderson, Karoun H Bagamian, Clint J Pecenka, et al.
Vaccine|October 12, 2023
Vaccine value profile for ShigellaWilliam P Hausdorff, John D Anderson, Karoun H Bagamian, et al.
Bulletin of the World Health Organization|January 2, 2024
Reassessing potential economic value and health impact of effective <i>Shigella</i> vaccinesWilliam P Hausdorff, John D Anderson, A Louis Bourgeois, et al.
Vaccine|July 13, 2024
Vaccine value profile for herpes simplex virusChristine Johnston, Suzanne Scheele, Laura Bachmann, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift AssaysSuzanne Scheele, Jennifer A Geiger, Amy E DeRocher, et al.
Pageof 2